Natera (NTRA) Earnings Date & Reports

Natera delivered standout Q1 results, with total revenue hitting $696.6 million, up 38.8% from $501.8 million YoY and well above consensus of ~$617 million. Product revenues drove the surge, fueled by higher test volumes and average selling prices (ASP).

Gross profit reached $450.8 million (64.7% margin), up from 63.1% YoY, thanks to scale and lower per-test costs. Operating expenses rose 36% to $538.6 million on headcount and trial spends, leading to an operating loss of $93.5 million. GAAP net loss widened to $85.1 million or $0.60 per diluted share (141.5 million weighted shares), versus $66.9 million or $0.50 loss last year; this slightly missed EPS consensus of -$0.53 to -$0.55 but reflected investments.

Key metrics shone: 1,013,600 tests processed (+18.5% YoY), 931,600 reported (+15.8%). Oncology volumes jumped 54.4% to 258,900, women's health hit second-highest growth since 2019. Cash position stood at $1,087.9 million; generated $11.8 million non-GAAP cash inflow. Guidance lifted: 2026 revenue $2.74-$2.82 billion, gross margin 64-66%, SG&A $1.125-$1.225 billion, R&D $800-$900 million, positive cash flow.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

Shares of NTRA closed up 2.20% at $219.82 on May 7 but fell 1.65% to $216.20 in after-hours, tempering enthusiasm despite revenue beat and guidance raise. The EPS miss, wider net loss, and 36% opex growth drew scrutiny, overshadowing volume records. Sentiment remains positive long-term on oncology momentum and cash positivity, but near-term caution prevails amid biotech peers' volatility.

Forward Outlook and Key Factors to Monitor

Natera's raised 2026 guidance signals confidence, with revenue midpoint up $120 million to $2.78 billion, implying ~22% growth over 2025 estimates. Gross margin expansion to 64-66% reflects operating leverage from scale.

Investors should track segment momentum: oncology (Signatera) volumes up 54%, women's health innovations like Fetal Focus, and organ health stability. Upcoming catalysts include 2026 data readouts, Japan expansion, and pan-cancer advancements.

R&D hike to $800-$900 million funds trials; monitor enrollment hits. Cost trends—opex discipline amid headcount—will test path to profitability. Reimbursement wins, ASP stability, and cash burn (positive inflow targeted) are pivotal amid industry margin pressures.

Balanced demand signals across franchises position Natera well, but execution on guidance amid macro healthcare shifts bears watching.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations